Abstract
A reliable measure to predict peripheral blood progenitor cell (PBPC) autograft CD34+ cell content is required to optimize the timing of PBPC collection. We prospectively examined the peripheral blood (PB) CD34+ cell count in 59 consecutive patients with various malignancies and analyzed the correlation between the PB CD34+ cell count and various parameters in the PBPC autograft. Two hundred and thirty-five collections were performed with a median of 4.0 collections per patient (range, 2–10). The median PB CD34+ cell count at the time of collection was 39 × 106/l (range, 0.0–285.6). The PBPC autograft parameters measured were the CD34+ cell, colony-forming unit granulocyte–macrophage (CFU-GM) and mononuclear cell (MNC) content. There was a strong linear correlation between PB CD34+ cells/l and autograft CD34+ cells/kg (r = 0.8477). The correlation with CFU-GM/kg (r = 0.5512) was weaker. There was no correlation between autograft CD34+ cells/kg and PB WBC (r = 0.0684), PB MNC (r = 0.1518) or PB platelet count (r = 0.2010). At our institution we aim to obtain a minimum of 0.5 × 106 CD34+ cells/kg with each day of collection. We demonstrate that such a collection can be reliably obtained if the PB CD34+ cell count exceeds 5.0 × 106/l.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chapple, P., Prince, H., Quinn, M. et al. Peripheral blood CD34+ cell count reliably predicts autograft yield. Bone Marrow Transplant 22, 125–130 (1998). https://doi.org/10.1038/sj.bmt.1701308
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701308
Keywords
This article is cited by
-
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
Bone Marrow Transplantation (2011)
-
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator
Leukemia (2009)
-
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF
Bone Marrow Transplantation (2005)
-
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study
Bone Marrow Transplantation (2000)
-
Docetaxel effectively mobilizes peripheral blood CD34+ cells
Bone Marrow Transplantation (2000)